What is Optinose?
Optinose operates at the intersection of pharmaceutical innovation and specialized patient care. Headquartered with a dual presence in the United States and Norway, the company focuses on addressing the unmet needs of patients managed by ENT and allergy specialists. Its business model centers on the development and commercialization of proprietary delivery technologies designed to improve therapeutic outcomes. By targeting specific, high-need medical segments, Optinose maintains a distinct competitive advantage, leveraging its specialized focus to drive market penetration and long-term value creation within the healthcare sector.
How much funding has Optinose raised?
Optinose has raised a total of $630.7M across 10 funding rounds:
Unspecified
$933K
Private Equity
$48.5M
Series C
$35M
Other Financing Round
$30M
Series D
$37M
Stock Offering
$138M
Debt
$100M
Stock Offering
$52.3M
Debt
$150M
Stock Offering
$39M
Unspecified (2002): $933K with participation from Andromeda Capital
Private Equity (2010): $48.5M led by Avista Capital Partners
Series C (2014): $35M supported by Avista Capital Partners, Entrepreneurs Fund, and WFD VENTURES
Other Financing Round (2015): $30M featuring Avista Capital Partners, WFD VENTURES, and Entrepreneurs Fund LP
Series D (2017): $37M backed by Avista Capital Partners, Fidelity Management and Research Company, and Entrepreneurs Fund
Stock Issuance/Offering (2017): $138M, investors not publicly disclosed
Debt (2018): $100M led by Athyrium Capital Management, LP
Stock Issuance/Offering (2018): $52.3M, investors not publicly disclosed
Debt (2019): $150M featuring Pharmakon Advisors, LP
Stock Issuance/Offering (2019): $39M, investors not publicly disclosed
Key Investors in Optinose
Avista Capital Partners
A private equity firm focused on growth-oriented investments across the healthcare, media, and energy sectors.
Entrepreneurs Fund
A venture capital arm of COFRA Holding that supports the formation and scaling of technology-driven global enterprises.
WFD VENTURES
An investment firm providing equity financing and industry expertise specifically to medical device and healthcare technology companies.
What's next for Optinose?
Looking ahead, the strategic deployment of capital remains central to Optinose's operational roadmap. Having secured significant financing through a mix of debt and equity, the company is well-positioned to accelerate its commercialization efforts and potentially expand its therapeutic pipeline. The focus will likely shift toward optimizing market access and deepening its footprint within the ENT and allergy specialty markets. As the firm matures, the emphasis on sustainable revenue growth and operational efficiency will be critical in justifying the substantial investment it has garnered to date, ensuring that its technological advancements translate into consistent clinical and financial performance.
See full Optinose company page
